" class="no-js "lang="en-US"> Aardvark Therapeutics Archives - Pharmtech Focus
Friday, January 27, 2023

Breaking News

Kinnate Biopharma Adds Global Business and Oncology Expertise to Board of Directors Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication New AI Tool Makes Speedy Gene Editing Possible European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer’s disease Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO Chews for Dogs Sharecare Launches VR Program to Improve Well-being of American Workforce Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer Nogra Pharma Announces Out-licensing Agreement with Torii Pharmaceutical for Japan for New Chemical Entity Topical Acne Treatment Cerebral Therapeutics Names Julie Foster as Chief Operating Officer

Sort by:

Date

Top Post

ProPharma Acquires UK Based Digital Lab Consulting | PTF

ProPharma Acquires UK Based Digital Lab Consulting

ProPharma Group (ProPharma) the leading global provider of regulatory, clinical, and quality services for the […]

Read more

Fundraising

 Aardvark Therapeutics

Aardvark Therapeutics, Inc., Completes $29m Series B Funding Led by Sorrento Therapeutics and Including Existing Investors and the Foundation for Prader-Willi Research

Aardvark Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing and commercializing novel small […]

  1. Kinnate Biopharma Adds Global Business and Oncology Expertise to Board of Directors

    Appointments

     Read more
  2. Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication

    Diseases

     Read more
  3. New AI Tool Makes Speedy Gene Editing Possible

    Diseases

     Read more
  4. European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer’s disease

    Diseases

     Read more
  5. Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

    Diseases

     Read more